MMP-1 Polyclonal Antibody

Applications

  • IHC-P
  • IF(IHC-P)

Reactivity

  • Mouse
  • Rat
Overview
Catalog # bs-0463R
Product Name MMP-1 Polyclonal Antibody
Applications IHC-P, IF(IHC-P)
Reactivity Mouse, Rat
Specifications
Conjugation Unconjugated
Host Rabbit
Source KLH conjugated synthetic peptide derived from rat MMP1
Immunogen Range 430-464/464
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.
Target
Gene ID 300339
Subcellular location Secreted
Synonyms CLGN; CLG; 27 kDa interstitial collagenase; collagenase, fibroblast; Fibroblast collagenase; Interstitial collagenase; Matrix metallopeptidase 1 interstitial collagenase; Matrix metalloproteinase-1; Matrix metalloprotease 1; Matrix Metalloproteinase 1; MMP-1; MMP1; MMP1_HUMAN; OTTHUMP00000045866; MMP 1.
Background The matrix metalloproteinases (MMPs) are a family of at least eighteen secreted and membrane bound zincendopeptidases. Collectively, these enzymes can degrade all the components of the extracellular matrix, including fibrillar and non fibrillar collagens, fibronectin, laminin and basement membrane glycoproteins. In general, a signal peptide, a propeptide, and a catalytic domain containing the highly conserved zinc binding site characterizes the structure of the MMPs. In addition, fibronectin like repeats, a hinge region, and a C terminal hemopexin like domain allow categorization of MMPs into the collagenase, gelatinase, stomelysin and membrane type MMP subfamilies. All MMPs are synthesized as proenzymes, and most of them are secreted from the cells as proenzymes. Thus, the activation of these proenzymes is a critical step that leads to extracellular matrix breakdown. MMPs are considered to play an important role in wound healing, apoptosis, bone elongation, embryo development, uterine involution, angiogenesis and tissue remodeling, and in diseases such as multiple sclerosis, Alzheimer's, malignant gliomas, lupus, arthritis, periodontis, glumerulonephritis, atherosclerosis, tissue ulceration, and in cancer cell invasion and metastasis.
Application Dilution
IHC-P 1:200-400
IF(IHC-P) 1:50-200